about
In Vivo Knockdown of Pathogenic Proteins via Specific and Nongenetic Inhibitor of Apoptosis Protein (IAP)-dependent Protein Erasers (SNIPERs).Development of protein degradation inducers of oncogenic BCR-ABL protein by conjugation of ABL kinase inhibitors and IAP ligands.(-)-Ternatin inhibits adipogenesis and lipid metabolism in 3T3-L1 cells.Importance of the backbone conformation of (-)-ternatin in its fat-accumulation inhibitory activity against 3T3-L1 adipocytes.Structure-based hybridization of the bioactive natural products rhizonin A and ternatin leading to a selective fat-accumulation inhibitor against 3T3-L1 adipocytes.Design, synthesis, and biological evaluation of biotin-labeled (-)-ternatin, a potent fat-accumulation inhibitor against 3T3-L1 adipocytes.Whole structure-activity relationships of the fat-accumulation inhibitor (-)-ternatin: recognition of the importance of each amino acid residue.Biological activity, structural features, and synthetic studies of (-)-ternatin, a potent fat-accumulation inhibitor of 3T3-L1 adipocytes.Synthesis and inhibitory effect on fat accumulation of (-)-ternatin derivatives modified in the beta-OH-D-Leu(7) moiety.Targeting the Allosteric Site of Oncoprotein BCR-ABL as an Alternative Strategy for Effective Target Protein Degradation.Fragment-based drug discovery of potent and selective MKK3/6 inhibitors.Derivatization of inhibitor of apoptosis protein (IAP) ligands yields improved inducers of estrogen receptor α degradation.Different Degradation Mechanisms of Inhibitor of Apoptosis Proteins (IAPs) by the Specific and Nongenetic IAP-dependent Protein Eraser (SNIPER)Pharmacological difference between degrader and inhibitor against oncogenic BCR-ABL kinaseConvergent synthesis and in vivo inhibitory effect on fat accumulation of (-)-ternatin, a highly N-methylated cyclic peptide
P50
Q36268420-1DF9F8F5-7CB1-4C62-B4AE-93C43A954AA0Q41247551-B4FE94C8-62DF-4EAC-A400-77B8E71FC9DAQ42622126-4B3EE476-4390-4210-8FCC-4782BEDF8EF2Q42803582-DAC3BAE9-AFD3-4E53-83C8-E420BF33AF72Q42804908-73880C1A-4606-4440-A28B-8485796CA42AQ42806016-6D82E377-0B02-495B-A111-9C6047707F9BQ42808422-713CDC00-CF22-4BD6-B9B7-A8DCF3DFE9FCQ42818376-83CEB111-D0CD-4B6D-AA0B-EEF64A4C080AQ42819396-12300225-4AA3-46D1-9712-8BF4462AA2C6Q45873447-D40A227D-07E3-45D1-81E1-4E33B4648DB7Q46217930-4FA4ABD5-043E-49FC-9C19-3F05EEE197EFQ52653329-CBC9AE0D-9946-462E-B9B2-52BD0DA03757Q58113226-E8150F43-A880-4E1E-A1B1-A135E7B0EBBEQ58756135-790B4A9C-1C23-4E00-8960-296BA02AB910Q80523611-2EEA46B5-072F-4678-A6DF-12A539A86060
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Kenichiro Shimokawa
@ast
Kenichiro Shimokawa
@en
Kenichiro Shimokawa
@es
Kenichiro Shimokawa
@nl
Kenichiro Shimokawa
@sl
type
label
Kenichiro Shimokawa
@ast
Kenichiro Shimokawa
@en
Kenichiro Shimokawa
@es
Kenichiro Shimokawa
@nl
Kenichiro Shimokawa
@sl
prefLabel
Kenichiro Shimokawa
@ast
Kenichiro Shimokawa
@en
Kenichiro Shimokawa
@es
Kenichiro Shimokawa
@nl
Kenichiro Shimokawa
@sl
P106
P31
P496
0000-0003-1982-0407